Distinct Patient, Tumour, Treatment Characteristics and a Different Pattern and Risk of Survival Events Over Time Between Young BRCA1/2 Carriers By Ogkologos - March 10, 2025 818 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a global cohort of patients harbouring germline pathogenic/likely pathogenic variants in BRCA1 or BRCA2 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Health inequalities: Why do people smoke if they know it’s bad... April 1, 2022 Mark Hoppus Of Blink-182 Announces He’s Cancer-Free October 8, 2021 NALIRIFOX Improves Survival Compared with Nab-paclitaxel Plus Gemcitabine in First-Line Treatment... September 22, 2023 HER2 Expression is a Determinant of Sensitivity to Trastuzumab Deruxtecan in... August 7, 2023 Load more HOT NEWS The Cancer Moonshot: Moving from Planning to Research Occurrence of Interstitial Lung Disease Related to Trastuzumab Deruxtecan in Patients... Combining Radiotherapy with SOC Plus Abiraterone Improves rPFS in Patients with... Coronavirus and cancer – July updates